Clinical trials: Standard Therapy
Breast Cancer Female
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study.
- Trial name
- ADAPTlate (NCT04565054)
- Testing
- Abemaciclib 50 MG; 150mg 1-0-1 per os
- Where
- 85 sites in Germany, Poland and 1 more
- Volunteers
- 1,260 people
- Sponsor
- Women's Cancer Study Group GmbH
Bladder Cancer, Urothelial Carcinoma (UC)
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options…
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Oligometastasis
- Trial name
- ASTRA (NCT07413523)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Submassive Pulmonary Embolism
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a combined therapy of Drotrecogin alfa…
- Trial name
- NCT00191724
- Testing
- Drotrecogin Alfa (Activated), Enoxaparin
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Lupus Nephritis
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
- Trial name
- NCT07767188
- Testing
- obinutuzumab (RO5072759)
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Zhao Minghui
Neurogenic Bladder
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy for children with neurogenic bladder due to spina bifida and compare results with standard oral oxybutynin therapy.
- Trial name
- NCT01716624
- Testing
- Oxybutynin, Botulinum Toxin A injection
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
- Trial name
- ACTICCA-1 (NCT02170090)
- Testing
- Gemcitabine, Cisplatin, Capecitabine
- Where
- 67 sites in Australia, Austria and 6 more
- Volunteers
- 789 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death…
- Trial name
- NCT07454018
- Testing
- Iparomlimab/Tuvonralimab
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Optimal ribavirin dosages are essential in achieving SVR (sustained virological response). Several studies have shown higher SVR rates in patients receiving higher doses of ribavirin.
- Trial name
- VIRID (NCT00662220)
- Testing
- ribavirin
- Where
- 27 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- Foundation for Liver Research
Hypovolemic Shock
A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
This is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening…
- Trial name
- NCT05956418
- Testing
- Centhaquine
- Where
- 17 sites in India
- Volunteers
- 400 people
- Sponsor
- Pharmazz, Inc.
Standard of Care, P2P Intervention
Peer to Peer (P2P): Mental Health Interventions With Persons With Substance Use Disorders
This study provides substance use and mental health peer support services to address behavioral health disparities in rural areas.
- Trial name
- P2P (NCT06803810)
- Testing
- P2P Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Prisma Health-Upstate
Venous Leg Ulcer
A Multicentre European Study to Evaluate Granulox® Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).
The investigation is designed as an open label, randomized, prospective, assessor blinded, multi centre investigation. 254 evaluable subjects will be randomized to either standard of care group or standard of care with Granulox…
- Trial name
- Granulox01 (NCT04181320)
- Testing
- Venous Leg Ulcer Standard of Care with Granulox
- Where
- 27 sites in Croatia, Czechia and 5 more
- Volunteers
- 128 people
- Sponsor
- Molnlycke Health Care AB
Clavicle Fracture
Efficacy of Self - Adjustable Clavicular Brace Versus Standard Clavicular Brace for Treatment of Mid Shaft Clavicle Fracture: A Randomized Controlled Study
A randomized control trial was conducted to compare the outcomes of conservative management for closed midshaft clavicular fractures using self-adjustable clavicular brace and standard clavicular brace.
- Trial name
- NCT06276218
- Testing
- Clavicular brace
- Where
- Thailand
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Pretreated Metastatic Colorectal Cancer
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic…
- Trial name
- REMETY (NCT03305913)
- Testing
- TAS 102, Regorafenib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AIO-Studien-gGmbH
Breast Cancer
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
This is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4/6 inhibitors and Fulvestrant in patients with…
- Trial name
- NCT07117630
- Testing
- L-Ornithine L-Aspartate, CDK4/6 inhibitor, Fulvestrant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute…
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma
- Trial name
- NCT01190930
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- 243 sites in United States, Australia and 5 more
- Volunteers
- 9,350 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
The purpose of this research is to estimate the effectiveness of a response adapted approach with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed standard risk multiple myeloma.
- Trial name
- NCT01054144
- Testing
- Lenalidomide, Prednisone, Dexamethasone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Urinary Tract Infections in Children
A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.
This is a retrospectively-controlled clinical trial that will examine the rate of positive UTI cases among pediatrics entered into the Emergency Department and whose urine is withdrawn using the PedSCath Pediatric Sampling…
- Trial name
- NCT04763967
- Testing
- PedSCath Pediatric Urinary Catheter, Standard of Care
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Big Blue Biotech, Inc.
ADHD
ADHD Treatment for Latino Families
The current pilot study aims to close the existing gap in our knowledge about effective psychosocial treatments for Latino families by providing preliminary data regarding the acceptability and efficacy of a culturally-modified…
- Trial name
- NCT02317692
- Testing
- Parent training
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Marquette University
Recurrent Glioblastoma
VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma
VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery
- Trial name
- NCT03750071
- Testing
- VXM01, Avelumab
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Vaximm GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.